Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170540 · ClinicalTrials.gov registry record · Phase 2
UNC Cashew Sublingual Immunotherapy
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Not yet
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT07170540: Clinical Trial Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
NCT07170540 is a Phase 2 study that has not yet begun recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07170540, a Phase 2 study, has not yet begun recruiting, sponsored by University of North Carolina, Chapel Hill.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The CASCADES study will investigate the safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of cashew allergy in children ages 1-11 years old. Primary efficacy will be assessed after 18 months of cashew SLIT. Lab studies and an oral food challenge after 6 months of cashew SLIT will help determine how quickly cashew SLIT begins to take effect.
Primary Outcome
Percentage of participants tolerating \>/= 1043 mg during cashew DBPCFC at month 18
Interventions
- DRUG Cashew sublingual immunotherapy
- DRUG Placebo sublingual immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What is known before NCT07170540 opens enrollment
NCT07170540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Cashew sublingual immunotherapy is the first listed.
NCT07170540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07170540 about?
NCT07170540 is a clinical study titled "UNC Cashew Sublingual Immunotherapy". The CASCADES study will investigate the safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of cashew allergy in children ages 1-11 years old. Primary efficacy will be assessed after 18 months of cashew SLIT. Lab studies and an oral food challenge after 6 months of cashew SLIT w...
What is the current status of trial NCT07170540?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2026-06. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07170540?
The interventions under investigation include: Cashew sublingual immunotherapy (DRUG), Placebo sublingual immunotherapy (DRUG).
Who is sponsoring clinical trial NCT07170540?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07170540's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia